Heterocyclic Compounds

Matches 101 - 150 out of 36,796	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/059249A1	M4 ACTIVATORS/MODULATORS AND USES THEREOF The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...
WO/2024/059010A1	COMPOUNDS FOR TREATING CANCER The present application relates to compounds of Formula (A), as defined herein, and pharmaceutically acceptable salts thereof, as well as processes for preparing compounds of Formula (A), and pharmaceutically acceptable salts thereof. Th...
WO/2024/059210A2	6,5 WESTERN CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME Negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatr...
WO/2023/159307A9	POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Disclosed are compounds and pharmaceutically acceptable salts of formula (I), which feature either a N-(1H-pyrazol-3-yl)pyridin-2-amine or a N-(1H-pyrazol-3-yl)pyrimidin-4-amine core structure. These compounds may be used in the treatmen...
WO/2024/059200A1	NEK7 INHIBITORS Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): (I) or a stereoisomer, tautomer, or salt thereof, wherein A, W, X, Y, Z, R1, and R2 are as defined herein. Methods associated with preparatio...
WO/2024/059781A1	NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ...
WO/2024/059845A1	SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurolo...
WO/2024/056063A1	COMPOUND CONTAINING HEXAHYDRO-SPIRO [CYCLOPROPANE-1,2'-PYRROLIZINE] The present application belongs to the field of pharmaceuticals, and relates to a series of compounds containing hexahydro-spiro[cyclopropane-1,2'-pyrrolizine], and particularly, to a compound represented by formula (III), a stereoisomer...
WO/2024/059212A2	6,6 WESTERN CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME Negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatr...
WO/2024/059220A2	6,5 SOUTHWESTERN CORE COMPOUNDS AS MGLU5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME Negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatr...
WO/2024/055195A1	HIGH-EFFICIENCY ORGANIC ELECTROLUMINESCENT DEVICE AND PREPARATION METHOD THEREFOR The present invention relates to a high-efficiency organic electroluminescent device and a preparation method therefor. A hole injection layer, a hole transport layer, an electron blocking layer, a light-emitting layer, a hole blocking l...
WO/2024/055992A1	TRICYCLIC COMPOUND AND USE THEREOF The present disclosure relates to a tricyclic compound represented by formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in preventing or treating a PI3Kα-related disease.
WO/2024/056782A1	SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER The application relates to sulfone-substituted pyrido[3,4-d]pyrimidine compounds of general formula (I), to pharmaceutical compositions and combinations comprising them and their medical use for the treatment or prophylaxis of hyperproli...
WO/2024/059524A1	PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
WO/2024/059186A1	N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.The present invention provides isoquinoline derivatives of for...
WO/2024/056091A1	PYRIDONOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF The present invention relates to a pyridonopyrimidine derivative as an RSK protein kinase inhibitor and use thereof. Specifically, the present invention relates to a compound represented by formula I, a pharmaceutical composition compris...
WO/2024/054919A1	SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be useful in the treatment of conditions such as depression and related disorders. Orally available formulations and other ph...
WO/2024/051631A1	MACROCYCLIC IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Disclosed are a macrocyclic imidazo[1,2-b]pyridazine compound represented by formula (I) or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer, a tautomer thereof or an isomer mixture thereof, or a...
WO/2024/052690A1	NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein Q, RL and RR are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatm...
WO/2024/050742A1	BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY Providing certain bifunctional compounds that cause degradation of K-ras G12D via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by K-ras G12D. Also provided are pharmaceutical compositions c...
WO/2024/054807A1	COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS Provided is a pharmaceutical composition including a metal channel activator and a TDP-43 modulator. Also provided is a method of treating a depressive disorder, including administering the pharmaceutical composition. Also provided is a ...
WO/2024/054469A1	ISOQUINOLONES AS PI3K INHIBITORS Novel PI3K inhibitors of the general formula (1) are described along with methods of their preparation and their use in the treatment of diseases associated with the elevation or activation of the PI3K pathway, wherein R1 to R8 are as de...
WO/2024/054814A1	CO-CRYSTALS OF 4-[4-[3-CHLORO-4-[1-(2-PYRIDYL)-2-HYDROXY-ETHOXY]PYRAZOLO[1,5-A]PYRIDIN-6-YL]-5- METHYL- TRIAZOL-1-YL]PIPERIDINE-1 -CARBONITRILE DERIVATIVES WITH GALLIC ACID AND NICOTINE AMIDE The present invention relates to cocrystalline forms of 4-[4-[3- chloro-4-[l-(5-fluoro-2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[l ,5- a]pyridin-6-yl]-5-methyl-triazol-l-yl]piperidine-l-carbonitr ile, R- enantiomer ("Isomer 2"), with gallic a...
WO/2024/054647A1	4-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-7-NAPHTHALENE-PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF THE KRAS(G12D) MUTANT ONCOPROTEINE FOR THE TREATMENT OF CANCER Provided are small molecule inhibitors of the KRAS(G12D) mutant oncoprotein having the structural formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
WO/2024/054512A1	AKT1 MODULATORS Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
WO/2024/052701A1	NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: I wherein Q1, R1, Ra, Rb, Rc, Rd, Re, A1 and A2 are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) an...
WO/2024/054808A1	PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR THE TREATMENT OF CANCER The present invention provides compounds of the formula as fibroblast growth factor receptor 3 (FGFR3) inhibitors for the treatment of e.g. cancer, systemic sclerosis, fibrosis, pulmonary fibrosis, achondroplasia, thanatophoric dysplasia...
WO/2024/051727A1	PYRAZOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION, AND USE The present invention relates to a pyrazole derivative, a pharmaceutical a composition, and a use. The pyrazole derivative has a structure as represented by formula (I). The pyrazole derivative has good activity inhibition selectivity wi...
WO/2024/051778A1	COMPOUNDS, PREPARATION METHODS AND USES THEREOF Provided herein are compounds having a Formula II-4, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds in inhibiting PI3K in a cell, or in treati...
WO/2024/051784A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Provided are a nitrogen-containing heterocyclic compound, a pharmaceutical composition thereof, and use thereof. The structure of the nitrogen-containing heterocyclic compound is represented by formula I. The nitrogen-containing heterocy...
WO/2024/054956A1	HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE The invention provides heterobifunctional compounds which may bind to both an androgen receptor and BRD4 (bromodomain- containing protein 4). Also provided are pharmaceutical compositions comprising the same and their use in treating dis...
WO/2024/052512A1	HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions contain...
WO/2024/054749A2	INHIBITORS OF ENL/AF9 YEATS AND FLT3 Compounds and pharmaceutical compositions comprising compounds that inhibit ENL/AF9 YEATS and FLT3 are disclosed herein. Methods for suppressing oncogene expression in a cell, or for treating acute leukemias, using the compounds and phar...
WO/2024/052684A1	ANTIBODY DRUG CONJUGATE COMPRISING NMT INHIBITOR AND ITS USE The present invention relates to ADCs comprising a NMT inhibitor conjugated to an antibody via a linker, and related uses.
WO/2024/051717A1	COMPOUND AS PLK1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Provided are a class of compounds as PLK1 inhibitors as represented by formula (I). The compound and the composition containing same can inhibit PLK1, and thus can be used for preventing and/or treating PLK1-related diseases, such as tum...
WO/2024/052693A1	PRODRUGS Provided are compounds of the Formula II, and salts, hydrates and solvates thereof: (Formula (II) wherein R is as defined in the specification. The compounds are prodrugs of inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for ...
WO/2024/054540A1	LRRK2 INHIBITORS AND USES THEREOF The invention provides pyrazolo[1,5-a][1,3,5]benzotriazepinyl, pyrazolo[1,5-a]pyrido[3,4-f][1,3,5]triazepinyl and related tricyclic compounds that inhibit the activity of one or more kinases, more particularly the protein kinase leucine ...
WO/2024/054832A1	CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS Provided herein are compounds that act as molecular glues, inducing degradation of CK1α or CK1α/GSPT1, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and meth...
WO/2024/054926A1	KRAS G12D INHIBITORS The present disclosure relates to KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
WO/2023/146809A9	PLASMA KALLIKREIN INHIBITORS The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit...
WO/2024/051763A1	QUINAZOLINE HETEROCYCLIC DERIVATIVE OF KRAS MUTATION INHIBITOR FOR TREATING CANCER The present invention relates to an inhibitor having a quinazoline heterocyclic structure for treating cancer. Specifically, the present invention relates to a derivative having a quinazoline heterocyclic structure as shown in formula (I...
WO/2024/051667A1	SUBSTITUTED TRIAZOLE COMPOUND HAVING AXL INHIBITORY ACTIVITY Disclosed is a substituted triazole compound having AXL inhibitory activity represented by formula (I), which is used for treating and/or preventing AXL receptor tyrosine kinase-induced disorders.
WO/2024/052692A1	NOVEL COMPOUNDS AS CK2 INHIBITORS Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatm...
WO/2024/054591A1	RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE Provided herein are bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (Raf, such as c-Raf, A-Raf, and/or B-RAF).
WO/2024/051766A1	MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF The present disclosure relates to a compound of formula (I) or a salt, an enantiomer, a diastereomer, an isotope-enriched analogue, a solvate, a prodrug or a polymorph thereof, and the use thereof. Further provided in the present disclos...
WO/2024/050389A1	COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Provided is a pharmaceutical composition including a metal channel activator and an NMDA receptor antagonist. Also provided is a method of treating a depressive disorder, including administering the pharmaceutical composition. Also provi...
WO/2024/046454A1	HETEROARYL-SUBSTITUTED PYRIDOPYRROLIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF The present application relates to a heteroaryl-substituted pyridopyrrolidone derivative, and a pharmaceutical composition and the use thereof. The heteroaryl-substituted pyridopyrrolidone derivative has a structure as shown in formula (...
WO/2024/046420A1	FUSED BICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE The present disclosure relates to a fused bicyclic compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a fused bicyclic compound as shown in general formula (I), a ...
WO/2024/050370A1	HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
WO/2024/049760A1	CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV The present disclosure provides, in part, cyclic urea thiazolyl compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

Matches 101 - 150 out of 36,796	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >